Therapeutic approaches to multiple sclerosis: An update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies

BioDrugs

Volumn 24, Issue 4, 2010, Pages 249-274

  Ulzheimer, Jochen C ^a,b   Meuth, Sven G ^a,c   Bittner, Stefan ^a   Kleinschnitz, Christoph ^a   Kieseier, Bernd C ^d   Wiendl, Heinz ^c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b CARITAS KRANKENHAUS   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Immunomodulators, therapeutic use; Multiple sclerosis; Research and development

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; ABATACEPT; ACICLOVIR; ATORVASTATIN; AZITHROMYCIN; BETA1A INTERFERON; BHT 3009; BROMELAIN; CHEMOKINE RECEPTOR ANTAGONIST; CP 481715; DNA VACCINE; DOXYCYCLINE; EFALIZUMAB; GLATIRAMER; IBUDILAST; METHOTREXATE; MINOCYCLINE; MONOCLONAL ANTIBODY IDEC 131; MYELIN BASIC PROTEIN[82-98]; OKT 3; PIOGLITAZONE; PLACEBO; PRILIXIMAB; RG 2077; ROLIPRAM; ROSIGLITAZONE; ROVELIZUMAB; TORALIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VALACICLOVIR; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADD ON THERAPY; CELL DIFFERENTIATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DNA IMMUNIZATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; INFECTION; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; LOW DRUG DOSE; MESENCHYMAL STEM CELL TRANSPLANTATION; MONOTHERAPY; MULTIPLE SCLEROSIS; NAUSEA; NAUSEA AND VOMITING; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING; ADULT; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; CHEMOTAXIS, LEUKOCYTE; CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPLE SCLEROSIS; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINES, DNA;

EID: 77954583779     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11537160-000000000-00000     Document Type: Review

References (180)

1. Hohlfeld R, Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci U S A 2004 Oct 5; 101 Suppl. 2: 14599-14606
2. Kleinschnitz C, Meuth SG, Kieseier BC, et al. Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006. Endocr Metab Immune Disord Drug Targets 2007 Mar; 7 (1): 35-63
3. Friese MA, Montalban X, Willcox N, et al. The value of animal models for drug development in multiple sclerosis. Brain 2006; 129: 1940-1952
4. Hohlfeld R, Wiendl H. The ups and downs of multiple sclerosis therapeutics. Ann Neurol 2001 Mar; 49 (3): 281-284
5. Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002; 16 (3): 183-200
6. Hohlfeld R, Wekerle H. Immunological update on multiple sclerosis. Curr Opin Neurol 2001; 14 (3): 299-304
7. Adorini L. Immunotherapeutic approaches in multiple sclerosis. J Neurol Sci 2004 Aug 15; 223 (1): 13-24
8. Kasper LH, Everitt D, Leist TP, et al. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Curr Med Res Opin 2006 Sep; 22 (9): 1671-1678
9. Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008 Sep; 7 (9): 796-804
10. Feng J,Misu T, Fujihara K, et al. Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. Mult Scler 2004 Oct; 10 (5): 494-498
11. Paul F, Waiczies S, Wuerfel J, et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One 2008; 3 (4): e1928
12. Birnbaum G, Cree B, Altafullah I, et al. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2008 Oct 28; 71 (18): 1390-1395
13. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005 Jul; 5 (7): 521-531
14. Kikly K, Liu L, Na S, et al. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006 Dec; 18 (6): 670-675
15. Smith T, Hewson AK, Kingsley CL, et al. Interleukin-12 induces relapse in experimental allergic encephalomyelitis in the Lewis rat. Am J Pathol 1997 Jun; 150 (6): 1909-1917
16. Gran B, Zhang GX, Rostami A. Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination. Crit Rev Immunol 2004; 24 (2): 111-128
17. Brok HP, van Meurs M, Blezer E, et al. Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol 2002 Dec 1; 169 (11): 6554-6563
18. Aranami T, Yamamura T. Th17 Cells and autoimmune encephalomyelitis (EAE/MS). Allergol Int 2008 Jun; 57 (2): 115-120
19. Cooper AM, Khader SA. IL-12p40: an inherently agonistic cytokine. Trends Immunol 2007 Jan; 28 (1): 33-38
20. Holscher C. The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases. MedMicrobiol Immunol 2004 Feb; 193 (1): 1-17
21. Mattner F, Fischer S, Guckes S, et al. The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer. Eur J Immunol 1993 Sep; 23 (9): 2202-2208
22. Ling P, Gately MK, Gubler U, et al. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol 1995 Jan 1; 154 (1): 116-127
23. Yoshimoto T, Takeda K, Tanaka T, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFNgamma production. J Immunol 1998 Oct 1; 161 (7): 3400-3407
24. Costa GL, Sandora MR, Nakajima A, et al. Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit. J Immunol 2001 Aug 15; 167 (4): 2379-2387
25. Sommer N, Loschmann PA, Northoff GH, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1995 Mar; 1 (3): 244-248
26. Bielekova B, Orlowski R, Howard T, et al. Treatment of MS patients with selective PDE-4 inhibitor rolipram inhibits Th1/Th17 T cell responses, but fails to inhibit brain inflammatory activity. American Academy of Neurology 60th Annual Meeting; 2008 Apr 12-19; Chicago (IL)
27. Zhang HT. Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Curr Pharm Des 2009; 15 (14): 1688-1698
28. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000 Dec; 6 (12): 1399-1402
29. Zamvil SS, Steinman L. Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment ofMS. Neurology 2002 Oct 8; 59 (7): 970-971
30. Zhang X, Jin J, Peng X, et al. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL- 17 transcription factor RORC in CD4+ lymphocytes. J Immunol 2008 May 15; 180 (10): 6988-6996
31. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002 Nov 7; 420 (6911): 78-84
32. Stanislaus R, Gilg AG, Singh AK, et al. Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin. Neurosci Lett 2002 Nov 29; 333 (3): 167-170
33. Stanislaus R, Singh AK, Singh I. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J Neurosci Res 2001 Oct 15; 66 (2): 155-162
34. Ifergan I, Wosik K, Cayrol R, et al. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol 2006 Jul; 60 (1): 45-55
35. NathN,Giri S, PrasadR, et al. Potential targets of 3-hydroxy-3- methylglutaryl coenzymeAreductase inhibitor for multiple sclerosis therapy. J Immunol 2004 Jan 15; 172 (2): 1273-1286
36. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsingremitting multiple sclerosis. Lancet 2004 May 15; 363 (9421): 1607-1608 (Pubitemid 38625664)
37. Goldman MD, Cohen JA. Statins to treat multiple sclerosis: friend or foe? Neurology 2008 Oct 28; 71 (18): 1386-1387
38. NeuhausO, Strasser-Fuchs S, Fazekas F, et al. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 2002 Oct 8; 59 (7): 990-997
39. Sellner J, Greeve I, Findling O, et al. Effect of interferon-beta and atorvastatin on Th1/Th2 cytokines in multiple sclerosis. Neurochem Int 2008 Jul; 53 (1-2): 17-21
40. Kieseier BC, Archelos JJ, Hartung HP. Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Arch Neurol 2004 Jun; 61 (6): 929-932
41. Miron VE, Zehntner SP, Kuhlmann T, et al. Statin therapy inhibits remyelination in the central nervous system. Am J Pathol 2009 May; 174 (5): 1880-1890
42. Frauwirth KA, Thompson CB. Activation and inhibition of lymphocytes by costimulation. J Clin Invest 2002 Feb; 109 (3): 295-299
43. Kobata T, Azuma M, Yagita H, et al. Role of costimulatory molecules in autoimmunity. Rev Immunogenet 2000; 2 (1): 74-80
44. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19: 225-252
45. Anderson DE, Sharpe AH, Hafler DA. The B7-CD28/CTLA-4 costimulatory pathways in autoimmune disease of the central nervous system. Curr Opin Immunol 1999 Dec; 11 (6): 677-683
46. Anderson DE, Bieganowska KD, Bar-Or A, et al. Paradoxical inhibition of T-cell function in response to CTLA-4 blockade: heterogeneity within the human T-cell population. Nat Med 2000 Feb; 6 (2): 211-214
47. Buck D, Kroner A, Rieckmann P, et al. Analysis of the C/T(-1) single nucleotide polymorphism in the CD40 gene in multiple sclerosis. Tissue Antigens 2006 Oct; 68 (4): 335-338
48. Maurer M, Loserth S, Kolb-Maurer A, et al. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 ( CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 2002 Apr; 54 (1): 1-8
49. Westhovens R, Verschueren P. Translating co-stimulation blockade into clinical practice [abstract]. Arthritis Res Ther 2008; 10 Suppl. 1: S4
50. Viglietta V, Bourcier K, Buckle GJ, et al. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology 2008 Sep 16; 71 (12): 917-924
51. Fieschi C. A phase II randomised, double-blind, placebo-controlled study to evaluate the preliminary efficacy and safety of abatacept, a selective costimulation modulator, in patients with relapsing-remitting multiple sclerosis [abstract no. 0140]. 15th Meeting of the European Neurological Society; 2005 Jun 18-22; Vienna
52. Dumont FJ. IDEC-131: IDEC/Eisai. Curr Opin Investig Drugs 2002 May; 3 (5): 725-734
53. Couzin J. Drug discovery: magnificent obsession. Science 2005 Mar 18; 307 (5716): 1712-1715
54. Pershadsingh HA. Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin Investig Drugs 2004 Mar; 13 (3): 215-228
55. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002 Jun; 2 (6): 389-400
56. Hurwitz AA, Sullivan TJ, Krummel MF, et al. Specific blockade of CTLA- 4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J Neuroimmunol 1997 Mar; 73 (1-2): 57-62
57. Hurwitz AA, Sullivan TJ, Sobel RA, et al. Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. Proc Natl Acad Sci U S A 2002 Mar 5; 99 (5): 3013-3017
58. Karandikar NJ, Eagar TN, Vanderlugt CL, et al. CTLA-4 downregulates epitope spreading and mediates remission in relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 2000 Sep 22; 109 (2): 173-180
59. Ligers A, Xu C, Saarinen S, et al. The CTLA-4 gene is associated with multiple sclerosis. J Neuroimmunol 1999 Jun 1; 97 (1-2): 182-190
60. Fukazawa T,Yanagawa T, Kikuchi S, et al. CTLA-4 gene polymorphism may modulate disease in Japanese multiple sclerosis patients. J Neurol Sci 1999 Dec 1; 171 (1): 49-55
61. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991 Sep 1; 174 (3): 561-569
62. Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 2006 Mar; 24 (3): 233-238
63. Arnason B. The role of cytokines in multiple sclerosis. Neurology 1995 Jun; 45 (6 Suppl. 6): S54-5
64. Bluestone JA. CTLA-4Ig is finally making it: a personal perspective. Am J Transplant 2005 Mar; 5 (3): 423-424
65. Quezada SA, Jarvinen LZ, Lind EF, et al. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004; 22: 307-328
66. Daoussis D, Andonopoulos AP, Liossis SN. Targeting CD40L: a promising therapeutic approach. Clin Diagn Lab Immunol 2004 Jul; 11 (4): 635-641
67. Howard LM, Miga AJ, Vanderlugt CL, et al. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J Clin Invest 1999 Jan; 103 (2): 281-290
68. Kawai T, Andrews D, Colvin RB, et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand [letter]. Nat Med 2000 Feb; 6 (2): 114
69. Pershadsingh HA, Heneka MT, SainiR, et al. Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J Neuroinflammation 2004 Apr 20; 1 (1): 3
70. Dello Russo C, Gavrilyuk V, Weinberg G, et al. Peroxisome proliferatoractivated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 2003 Feb 21; 278 (8): 5828-5836
71. Storer PD, Xu J, Chavis J, et al. Peroxisome proliferator-activated receptorgamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J Neuroimmunol 2005 Apr; 161 (1-2): 113-122
72. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 Oct 8; 366 (9493): 1279-1289
73. Diab A, Deng C, Smith JD, et al. Peroxisome proliferator-activated receptorgamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002 Mar 1; 168 (5): 2508-2515
74. Feinstein DL, Galea E, Gavrilyuk V, et al. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 2002 Jun; 51 (6): 694-702
75. Lovett-Racke AE, Hussain RZ, Northrop S, et al. Peroxisome proliferatoractivated receptor alpha agonists as therapy for autoimmune disease. J Immunol 2004 May 1; 172 (9): 5790-5798
76. Klotz L, Schmidt M, Giese T, et al. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol 2005 Oct 15; 175 (8): 4948-4955
77. Kaiser CC, Shukla DK, Stebbins GT, et al. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neuroimmunol 2009 Jun 25; 211 (1-2): 124-130
78. GlaxoSmithKline Clinical Study Register. Study No. 49653/452: A randomized, double-blind, parallel group, placebo-controlled study to investigate the safety, tolerability and efficacy of six months' administration of AVANDIA (rosiglitazone maleate) in subjects with Relapsing-Remitting Multiple Sclerosis (MS) [online]. Available from URL: http://www. gskclinicalstudyregister. com/files/pdf/23034.pdf [Accessed 2010 Jun 13]
79. BaggioliniM. Chemokines and leukocyte traffic. Nature 1998 Apr 9; 392 (6676): 565-568
80. Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 2005 Sep; 26 (9): 485-495
81. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006 Feb 9; 354 (6): 610-621
82. Columba-Cabezas S, Serafini B, Ambrosini E, et al. Induction of macrophage- derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. J Neuroimmunol 2002 Sep; 130 (1-2): 10-21
83. Sorensen TL, Trebst C, Kivisakk P, et al. Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J Neuroimmunol 2002 Jun; 127 (1-2): 59-68
84. OmariKM, John GR, Sealfon SC, et al. CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. Brain 2005 May; 128 (Pt 5): 1003-1015
85. Omari KM, John G, Lango R, et al. Role for CXCR2 and CXCL1 on glia in multiple sclerosis. Glia 2006 Jan 1; 53 (1): 24-31
86. Sorensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999 Mar; 103 (6): 807-815
87. Ubogu EE, Cossoy MB, Ransohoff RM. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci 2006 Jan; 27 (1): 48-55
88. Gaupp S, Pitt D, Kuziel WA, et al. Experimental autoimmune encephalomyelitis (EAE) in CCR2(-/-) mice: susceptibility in multiple strains. Am J Pathol 2003 Jan; 162 (1): 139-150
89. Fox RJ, Ransohoff RM. New directions inMS therapeutics: vehicles of hope. Trends Immunol 2004 Dec; 25 (12): 632-636
90. Ransohoff RM, Liu L, Cardona AE. Chemokines and chemokine receptors: multipurpose players in neuroinflammation. Int Rev Neurobiol 2007; 82: 187-204
91. Clucas AT, Shah A, Zhang YD, et al. Phase I evaluation of the safety, pharmacokinetics and pharmacodynamics of CP-481,715. Clin Pharmacokinet 2007; 46 (9): 757-766
92. Zipp F, Hartung HP, Hillert J, et al. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology 2006 Nov 28; 67 (10): 1880-1883
93. ReuX R, Schreiber V, Klein A, et al. Oral CCR1 antagonist BX 471 increases ICAM-3 expresion on RR-MS patients' CD14+ myelomonocytic cells [abstract]. 16th Meeting of the European Neurological Society; 2006 May 27-31; Lausanne
94. Bowen JD, Petersdorf SH, Richards TL, et al. Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis. Clin Pharmacol Ther 1998 Sep; 64 (3): 339-346
95. Minagar A, Alexander JS, Schwendimann RN, et al. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Arch Neurol 2008 Feb; 65 (2): 199-204
96. Yong VW, Zabad RK, Agrawal S, et al. Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J Neurol Sci 2007 Aug 15; 259 (1-2): 79-84
97. Zhang Y,Metz LM, Yong VW, et al. Pilot study of minocycline in relapsingremitting multiple sclerosis. Can J Neurol Sci 2008 May; 35 (2): 185-191
98. Zabad RK, Metz LM, Todoruk TR, et al. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler 2007 May; 13 (4): 517-526
99. Yadav V, Marracci G, Lovera J, et al. Lipoic acid in multiple sclerosis: a pilot study. Mult Scler 2005 Apr; 11 (2): 159-165
100. Elices MJ. BX-471 Berlex. Curr Opin Investig Drugs 2002 Jun; 3 (6): 865-869
101. Dhami H, Fritz CE, Gankin B, et al. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies. J Clin Pharm Ther 2009 Apr; 34 (2): 147-160
102. Bartholomaus I, Kawakami N, Odoardi F, et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009 Nov 5; 462 (7269): 94-98
103. Simmons DL, Buckley CD. Some new, and not so new, anti-inflammatory targets. Curr Opin Pharmacol 2005 Aug; 5 (4): 394-397
104. Rychly J, Nebe B. Therapeutic strategies in autoimmune diseases by interfering with leukocyte endothelium interaction. Curr Pharm Des 2006; 12 (29): 3799-3806
105. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebocontrolled trial of natalizumab for relapsing multiple sclerosis.NEngl J Med 2006 Mar 2; 354 (9): 899-910
106. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005 Jun; 4 (6): 510-518
107. Ransohoff RM. "Thinking without thinking" about natalizumab and PML. J Neurol Sci 2007 Aug 15; 259 (1-2): 50-52
108. European Medicines Agency (EMEA). EU-wide recall of Raptiva (efalizumab) to be intiated [press release]. London: EMEA, 2009 Jun 8 [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/ EPAR/raptiva/34625509en.pdf [Accessed 2010 May 31]
109. Yong VW, Power C, Forsyth P, et al. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001 Jul; 2 (7): 502-511
110. Kieseier BC, Kiefer R, Clements JM, et al. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 1998 Jan; 121 (Pt 1): 159-166
111. Marracci GH, Jones RE, McKeon GP, et al. Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J Neuroimmunol 2002 Oct; 131 (1-2): 104-114
112. Orsucci D, Calsolaro V, Mancuso M, et al. Neuroprotective effects of tetracyclines: molecular targets, animal models and human disease. CNS Neurol Disord Drug Targets 2009 Jun; 8 (3): 222-231
113. Metz LM, Li D, Traboulsee A, et al. Glatiramer acetate in combination with minocycline in patients with relapsing-remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. Mult Scler 2009 Oct; 15 (10): 1183-1194
114. Correale J, Farez M, Gilmore W. CNS Vaccines for multiple sclerosis: progress to date. Drugs 2008; 22 (3): 175-198
115. Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009 Mar; 8 (3): 244-253
116. Saccardi R, Kozak T, Bocelli-Tyndall C, et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler 2006 Dec; 12 (6): 814-823
117. DaumerM, Griffith LM, Meister W, et al. Survival, and time to an advanced disease state or progression, of untreated patients with moderately severe multiple sclerosis in a multicenter observational database: relevance for design of a clinical trial for high dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation. Mult Scler 2006 Apr; 12 (2): 174-179
118. Roccatagliata L, Rocca M, Valsasina P, et al. The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Mult Scler 2007 Sep; 13 (8): 1068-1070
119. Shevchenko YL, Novik AA, Kuznetsov AN, et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp Hematol 2008 Aug; 36 (8): 922-928
120. Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003 Oct 1; 102 (7): 2364-2372
121. Fassas A, Passweg JR, Anagnostopoulos A, et al. Hematopoietic stem cell transplantation for multiple sclerosis: a retrospective multicenter study. J Neurol 2002 Aug; 249 (8): 1088-1097
122. Karussis D, Kassis I, Kurkalli BG, et al. Immunomodulation and neuroprotection with mesenchymal bonemarrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases. J Neurol Sci 2008 Feb 15; 265 (1-2): 131-135
123. Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J, et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J Immunol 2007 Mar; 4 (1): 50-57
124. Warren KG, Catz I, Ferenczi LZ, et al. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month doubleblind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol 2006 Aug; 13 (8): 887-895
125. Garren H, Robinson WH, Krasulova E, et al. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 2008 May; 63 (5): 611-620
126. Bar-Or A, Vollmer T, Antel J, et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol 2007 Oct; 64 (10): 1407-1415
127. Muraro PA, Cassiani-Ingoni R, Martin R. Using stem cells in multiple sclerosis therapies. Cytotherapy 2004; 6 (6): 615-620
128. Burt RK, Cohen B, Rose J, et al. Hematopoietic stem cell transplantation for multiple sclerosis. Arch Neurol 2005 Jun; 62 (6): 860-864
129. Karussis DM, Slavin S, Lehmann D, et al. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. J Immunol 1992 Mar 15; 148 (6): 1693-1698
130. Burt RK, Padilla J, Begolka WS, et al. Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis. Blood 1998 Apr 1; 91 (7): 2609-2616
131. Mancardi GL, Saccardi R, Filippi M, et al. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 2001 Jul 10; 57 (1): 62-68
132. Saccardi R, Mancardi GL, Solari A, et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 2005 Mar 15; 105 (6): 2601-2607
133. Nash RA, Stuve O, Bowen JD, et al. Autologous HSCT for advanced MS: is the glass half-empty or really half-full? [letter]. Brain 2008 Feb; 131 (Pt 2): e89; author reply e90
134. Samijn JP, te Boekhorst PA, Mondria T, et al. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatry 2006 Jan; 77 (1): 46-50
135. Sullivan KM, Muraro P, Tyndall A. Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. Biol Blood Marrow Transplant 2010 Jan; 16 (1 Suppl.): S48-56
136. Northwestern University. Stem cell therapy for patients with multiple sclerosis failing interferon A randomized study [ClinicalTrials.gov identifier: NCT00273364]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Jun 3]
137. Mondria T, Lamers CH, te Boekhorst PA, et al. Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008 Sep; 79 (9): 1013-1015
138. Metz I, Lucchinetti CF, Openshaw H, et al. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain 2007 May; 130 (Pt 5): 1254-1262
139. Kassis I, Grigoriadis N, Gowda-Kurkalli B, et al. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 2008 Jun; 65 (6): 753-761
140. Karussis D, Kassis I. The potential use of stem cells in multiple sclerosis: an overview of the preclinical experience. Clin Neurol Neurosurg 2008 Nov; 110 (9): 889-896
141. Bai L, Lennon DP, Eaton V, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009 Aug 15; 57 (11): 1192-1203
142. Aharonowiz M, Einstein O, Fainstein N, et al. Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis. PLoS One 2008; 3 (9): e3145
143. Slavin S, Kurkalli BG, Karussis D. The potential use of adult stem cells for the treatment of multiple sclerosis and other neurodegenerative disorders. Clin Neurol Neurosurg 2008 Nov; 110 (9): 943-946
144. University of Cambridge. Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) [ClinicalTrials.gov identifier: NCT00395200]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http:// www.clinicaltrials.gov [Accessed 2010 Jun 3]
145. Freedman MS, Bar-Or A, Atkins HL, et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler 2010 Apr; 16 (4): 503-510
146. Hohol MJ, Khoury SJ, Cook SL, et al. Three-year open protocol continuation study of oral tolerization with myelin antigens in multiple sclerosis and design of a phase III pivotal trial. Ann N Y Acad Sci 1996 Feb 13; 778: 243-250
147. Darlington C. MBP-8298, a synthetic peptide analog of myelin basic protein for the treatment of multiple sclerosis. Curr Opin Mol Ther 2007 Aug; 9 (4): 398-402
148. Dirucotide does not meet primary endpoint in phase III MAESTRO-01 trial: in secondary progressive multiple sclerosis [press release]. BioMS [online]. Available from URL: http://www.biomsmedical.com/display-press-release. php?id=198 [Accessed 2010 Jun 3]
149. Moses Jr H, Sriram S. An infectious basis for multiple sclerosis: perspectives on the role of Chlamydia pneumoniae and other agents. BioDrugs 2001; 15 (3): 199-206
150. Lycke J, Svennerholm B, Hjelmquist E, et al. Acyclovir treatment of relapsingremitting multiple sclerosis: a randomized, placebo-controlled, double-blind study. J Neurol 1996 Mar; 243 (3): 214-224
151. Friedman JE, Zabriskie JB, Plank C, et al. A randomized clinical trial of valacyclovir in multiple sclerosis. Mult Scler 2005 Jun; 11 (3): 286-295
152. Bech E, Lycke J, Gadeberg P, et al. A randomized, double-blind, placebocontrolled MRI study of anti-herpes virus therapy in MS. Neurology 2002 Jan 8; 58 (1): 31-36
153. Sriram S, Yao SY, Stratton C, et al. Pilot study to examine the effect of antibiotic therapy on MRI outcomes in RRMS. J Neurol Sci 2005 Jul 15; 234 (1-2): 87-91
154. Baumhackl U, Kappos L, Radue EW, et al. A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis. Mult Scler 2005 Apr; 11 (2): 166-168
155. Ascherio A, Munger KL, Lennette ET, et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001; 286 (24): 3083-3088
156. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985; 1 (8441): 1313-1315
157. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis: part I. The role of infection. Ann Neurol 2007 Apr; 61 (4): 288-299 (Pubitemid 46676728)
158. Giovannoni G, Cutter GR, Lunemann J, et al. Infectious causes of multiple sclerosis. Lancet Neurol 2006 Oct; 5 (10): 887-894
159. Lunemann JD,Kamradt T,Martin R, et al. Epstein-barr virus: environmental trigger of multiple sclerosis? J Virol 2007 Jul; 81 (13): 6777-6784
160. Cepok S, Zhou D, Srivastava R, et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 2005 May; 115 (5): 1352-1360
161. Lunemann JD, Edwards N, Muraro PA, et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 2006 Jun; 129 (Pt 6): 1493-1506
162. Sospedra M, Zhao Y, zur Hausen H, et al. Recognition of conserved amino acid motifs of common viruses and its role in autoimmunity. PLoS Pathog 2005 Dec; 1 (4): e41
163. Sriram S, Mitchell W, Stratton C. Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS. Neurology 1998 Feb; 50 (2): 571-572
164. Bashir K, Kaslow RA. Chlamydia pneumoniae and multiple sclerosis: the latest etiologic candidate. Epidemiology 2003 Mar; 14 (2): 133-134
165. Munger KL, Peeling RW, Hernan MA, et al. Infection with Chlamydia pneumoniae and risk ofmultiple sclerosis. Epidemiology 2003Mar; 14 (2): 141-147
166. Munger KL, DeLorenze GN, Levin LI, et al. A prospective study of Chlamydia pneumoniae infection and risk of MS in two US cohorts. Neurology 2004 May 25; 62 (10): 1799-1803
167. Griggs RC. Chlamydia: conflict and controversy [letter]. Neurology 2001 May 8; 56 (9): 1130
168. Yong VW, Wells J, Giuliani F, et al. The promise of minocycline in neurology. Lancet Neurol 2004 Dec; 3 (12): 744-751
169. Metz LM, Zhang Y, Yeung M, et al. Minocycline reduces gadoliniumenhancing magnetic resonance imaging lesions in multiple sclerosis [letter]. Ann Neurol 2004 May; 55 (5): 756
170. Maier K, Merkler D, Gerber J, et al. Multiple neuroprotective mechanisms of minocycline in autoimmuneCNS inflammation. Neurobiol Dis 2007 Mar; 25 (3): 514-525
171. Brundula V, Rewcastle NB, Metz LM, et al. Targeting leukocyteMMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002 Jun; 125 (Pt 6): 1297-1308
172. Kozik M. Activity of hydrolytic enzymes in a case of subacute multiple sclerosis. Pathol Eur 1973; 8 (2): 143-147
173. Baumhackl U, Fodermair S. Enzymtherapie bei Multipler Sklerose. Allgemeinmedizin 1990; 19: 169-172
174. Castell JV, Friedrich G, Kuhn CS, et al. Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake. Am J Physiol 1997 Jul; 273 (1 Pt 1): G139-46
175. Targoni OS, Tary-Lehmann M, Lehmann PV. Prevention of murine EAE by oral hydrolytic enzyme treatment. J Autoimmun 1999 May; 12 (3): 191-198
176. LugaresiA,CaporaleC, FarinaD, et al. Low-dose oralmethotrexate treatment in chronic progressive multiple sclerosis. Neurol Sci 2001 Apr; 22 (2): 209-210
177. Calabresi PA, Wilterdink JL, Rogg JM, et al. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 2002 Jan 22; 58 (2): 314-317
178. Gray OM, McDonnell GV, Forbes RB. A systematic review of oral methotrexate for multiple sclerosis. Mult Scler 2006 Aug; 12 (4): 507-510
179. Gray O, McDonnell GV, Forbes RB. Methotrexate for multiple sclerosis. Cochrane Database Syst Rev 2004 (2): CD003208
180. Cohen JA, Calabresi PA, Chakraborty S, et al. Avonex combination trial in relapsing-remittingMS: rationale, design and baseline data. Mult Scler 2008 Apr; 14 (3): 370-382